Table 1|.
Clinical and demographic characteristics of the intervention groups.
| Active (n = 14) | Control (n = 14) | |
|---|---|---|
| Number of previous MDEs (percentiles) | 25th = 1 50th = 2, 75th = 3 | 25th = 1 50th = 2, 75th = 10 |
| (range: 1–4) | (range: 1–20) | |
| Psychotic symptoms in previous MDE | 0 | 2 |
| Current medication | ||
| SSRI | 6 | 8 |
| SNRI | 3 | 1 |
| Tricyclic antidepressant (therapeutic dose) | 1 | 1 |
| Low dose tricyclic antidepressant add-on | 1 | 0 |
| Topiramate | 1 | 1 |
| No antidepressant medication | 4 | 4 |
| Benzodiazepines | 7 | 7 |
| Ritalin | 1 | 0 |
| Life-time co-morbidity | ||
| Bulimia nervosa | 1 | 0 |
| Anorexia nervosa | 0 | 1 |
| Panic disorder/agoraphobia | 3 | 1 |
| Social phobia | 2 | 0 |
| Obsessive Compulsive Disorder | 0 | 1 |
| Generalised Anxiety Disorder | 1 | 0 |
| Specific phobia | 1 | 3 |
| Health anxiety disorder | 0 | 1 |
| Multiple anxiety disorders | 1 | 3 |
| No anxiety disorder | 6 | 5 |
| Substance abuse | 0 | 1 |
| Alcohol abuse | 2 | 1 |
| Alcohol and substance abuse | 1 | 0 |
| No substance or alcohol abuse | 11 | 12 |
Participants in the Active and Control Intervention groups did not differ on median number of previous episodes despite higher 75th percentiles in the CONTROL group. Number of cases are reported. MDE, major depressive episode; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor. One participant in the CONTROL group (SUBJ0003) showed bipolar features on the MINI interview which were not deemed to meet criteria for bipolar disorder by the senior psychiatrist. Interestingly, this participant showed the highest connectivity for guilt relative to indignation at baseline of the whole study, yet the significant group differences in baseline connectivity for guilt vs. indignation remain even when excluding SUBJ0003 (t = 2.1, p = .05).